Literature DB >> 12734351

Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells.

Yuanqing Liu1, Jo A Van Ginderachter, Lea Brys, Patrick De Baetselier, Geert Raes, Anja B Geldhof.   

Abstract

Most of the mice bearing a s.c. BW-Sp3 lymphoma tumor mount a CD8(+) T cell-mediated response resulting in tumor regression. Nonetheless, tumor progression occurs in some of the recipients and is associated with CTL inactivity. We demonstrated that T cell-activating APC were induced in regressors whereas T cell suppressive myeloid cells predominated in the spleen of progressors. Indeed, in vitro depletion of either the adherent or the CD11b(+) populations restored T cell cytotoxicity and proliferation in these mice. This CTL inhibition was cell-to-cell contact-dependent but not mediated by NO. However, the same progressor suppressive cells prevented the activity of in vitro-restimulated CTLs derived from regressors in a cell-to-cell contact and NO-dependent fashion. Thus, either the NO-dependent or -independent suppressive pathway prevailed, depending on the target CTL population. In addition, the suppressive population expressed a high arginase activity, suggesting an association of the suppressive phenotype with alternatively activated (M2) myeloid cells. However, the high arginase activity is not directly involved in the suppressive process. Our results provide new insights for myeloid cell-mediated CTL inhibition during cancer progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734351     DOI: 10.4049/jimmunol.170.10.5064

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

Review 1.  Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells.

Authors:  Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  Semin Cancer Biol       Date:  2012-01-31       Impact factor: 15.707

2.  Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNFα and NO-dependent mechanism, promoting a tumor-supportive environment.

Authors:  Janna Michaeli; Merav E Shaul; Inbal Mishalian; Avi-Hai Hovav; Liran Levy; Lidia Zolotriov; Zvi Granot; Zvi G Fridlender
Journal:  Oncoimmunology       Date:  2017-08-16       Impact factor: 8.110

Review 3.  Role of immature myeloid cells in mechanisms of immune evasion in cancer.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2005-07-27       Impact factor: 6.968

4.  All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.

Authors:  Noweeda Mirza; Mayer Fishman; Ingo Fricke; Mary Dunn; Anthony M Neuger; Timothy J Frost; Richard M Lush; Scott Antonia; Dmitry I Gabrilovich
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

5.  Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression.

Authors:  Andrew L Doedens; Christian Stockmann; Mark P Rubinstein; Debbie Liao; Na Zhang; David G DeNardo; Lisa M Coussens; Michael Karin; Ananda W Goldrath; Randall S Johnson
Journal:  Cancer Res       Date:  2010-09-14       Impact factor: 12.701

Review 6.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.

Authors:  Theodore J Cory; Susan E Birket; Brian S Murphy; Cynthia Mattingly; Jessica M Breslow-Deckman; David J Feola
Journal:  J Antimicrob Chemother       Date:  2012-12-17       Impact factor: 5.790

Review 8.  Arginase: an emerging key player in the mammalian immune system.

Authors:  Markus Munder
Journal:  Br J Pharmacol       Date:  2009-09-17       Impact factor: 8.739

9.  Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.

Authors:  Paolo Serafini; Stephanie Mgebroff; Kimberly Noonan; Ivan Borrello
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

10.  The immunomodulatory glycan LNFPIII initiates alternative activation of murine macrophages in vivo.

Authors:  Olga Atochina; Akram A Da'dara; Mirjam Walker; Donald A Harn
Journal:  Immunology       Date:  2008-03-28       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.